This inventor holds 4 USPTO granted patents. Top assignee: Suntory Limited. Active years: 1987-1988.
Location History:
- Nara, JP (1987)
- Ikoma, JP (1988)
Company Filing History:
Years Active: 1987-1988
Title: Kayoko Imao: Innovator in Pharmaceutical Chemistry
Introduction
Kayoko Imao is a distinguished inventor based in Nara, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds aimed at improving cerebral insufficiency. With a total of 4 patents to her name, her work has garnered attention in both academic and industrial circles.
Latest Patents
Among her latest patents is a derivative of benzoquinonylphenyl alkanoic acid amide. This compound is characterized by the formula: ##STR1##, where X can be an oxygen atom, sulfur atom, or methylated nitrogen atom, Me represents methyl, and n is either 2 or 3. This derivative has shown effectiveness as a cerebral insufficiency improver. Another notable patent is for a diaryl butyric acid derivative, which has the general formula: ##STR1##. In this case, R.sup.1 can be a hydrogen atom, an alkyl group with 1 to 3 carbon atoms, or an acyl group with 2 to 4 carbon atoms, while R.sup.2 represents an alkyl group with 1 to 3 carbon atoms.
Career Highlights
Kayoko Imao has worked with prominent companies such as Suntory Limited, where she has applied her expertise in pharmaceutical research. Her innovative approaches have led to advancements in drug development and therapeutic applications.
Collaborations
Throughout her career, Kayoko has collaborated with esteemed colleagues, including Toshio Tatsuoka and Kenji Suzuki. These partnerships have facilitated the exchange of ideas and fostered a collaborative environment for research and development.
Conclusion
Kayoko Imao's contributions to pharmaceutical chemistry and her innovative patents highlight her role as a leading inventor in her field. Her work continues to impact the development of effective treatments for cerebral insufficiency and beyond.